|Assessment Status||Assessment process complete|
|Indication||For the prophylaxis of migraine in adults who have at least four migraine days per month.|
|Rapid review commissioned||02/12/2020|
|Rapid review completed||13/01/2021|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of galcanezumab (Emgality®) on the basis of the proposed price relative to currently available therapies.|
The HSE has approved reimbursement following confidential price negotiations March 2022.